XNW28012 / Evopoint - LARVOL DELTA

Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments (clinicaltrials.gov) - P1/2 | N=200 | Recruiting | Sponsor: Evopoint Biosciences Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2025 ➔ Dec 2023

Enrollment open • Trial initiation date • Cervical Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments (clinicaltrials.gov) - P1/2 | N=200 | Not yet recruiting | Sponsor: Evopoint Biosciences Inc.

New P1/2 trial • Oncology • Solid Tumor